Clinical trial BRUMIZE
Zanubrutinib in patients with Marginal Zone Lymphoma, a multicenter observational real-world ambispective study In France and Belgium (BGB-3111-MA-FR-BE-402)
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial open for recruitment |
| Trial type |
Prospective observational study
|
| Academic trial | Non |
| Sponsor | BeiGene |
| BECT Identifier | B3222025001614 |
| Inclusion criteria | - Adult patients diagnozed with R/R MZL- Previously treated with anti-CD20therapy- Patients aiming to receive, receiving or having received zanubrutinib |
| Last update |